BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release on the standalone and consolidated financial results of the Company for the quarter and financial year ended 31.03.2022, announced by us on 30.05.2022. BAL PHARMA LTD. - 524824 - Audited Financial Results For F.Y 2021-22.
The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2022. A copy of the Audited financials (Standalone and Consolidated) along with auditors report's are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Out Come Of The Board Meeting
The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2022. A copy of the Audited financials (Standalone and Consolidated) along with auditors report's are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. 3.Approved to redraft the Memorandum and Articles of Association of the Company as per the provisions of Companies Act,2013, subject to the approval of members at the ensuing Annual General Meeting. 4. Appointed Mr.Kotian Chittananda Damodar ( DIN # 09613054 ) as Additional Director ( Non Independent ) of the Company. The meeting commenced at 4.30 p.m and concluded at 6.00 p.m on 30.05.2022. BAL PHARMA LTD. - 524824 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance report for the financial year ended 31.03.2022. BAL PHARMA LTD. - 524824 - Board to consider Dividend
Bal Pharma Ltd has informed BSE that the meeting of Board of Directors of the Company is scheduled to be held on May 30, 2022, inter alia, to consider transacting the following business. 1. Approval of Audited Standalone and Consolidated financial results of the Company for the quarter and financial year ended March 31, 2022.2. To recommend dividend, if any for the financial year ended March 31, 2022.3. To decide on the book closure dates. 4. To convene the 35th Annual General Meeting of the Company,4. Other AGM related matters.Further, pursuant to amended provisions of SEBI (Prohibition ol Insider Trading Regulations), 2015 and as per the provisions of Code of Conduct of the Company, the trading window for dealing in securities of the Company by its designated persons/employees and their immediate relatives was closed from April 01, 2022 up to June 01, 2022 i.e 48 hours after declaration of financial results of the Company for the financial year ended March 31, 2022. BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Inter Alia Approval Of Audited Financial Results For F.Y Ended 31.03.2022.
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve 1.Audited financial results for the quarter and year ended 31.03.2022. 2.Recommendation of Dividend , if any for the F.Y 2021.22 3.To decide on the Book closure dates. 4. To convene the 35th Annual General Meeting of the Company. 5. Other AGM related matters. BAL PHARMA LTD. - 524824 - Certificate As Per Regulation 40(9) Of SEBI(LODR) Regulations,2015.
We are submitting to the exchange certificate from the Practicing Company Secretary certifying compliance with Regulation 40(9) of SEBI (LODR) Regulations , for half year ended 31.03.2022. BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Allotment
Pursuant to applicable provisions of Chapter V of SEBI (ICDR) Regulations, 2018 and Section 42 of the Companies Act,2013 & Companies (Prospectus and allotment of Securities) Rules, 2014 as amended from time to time and after having received the full consideration amount , the Board of Directors of the Company at its meeting held on today i.e 13.04.2022 has inter alia approved the allotment of 7,50,000 equity shares of Rs.10/- each to the following investor , upon conversion of Warrants allotted to him on preferential basis: Sl No Name of the Investor Category of Investor No of equity shares allotted Distinctive Numbers 01 Mr Shailesh Siroya Promoter 7,50,000 14822373 to 15572372 With this allotment, the paid-up equity share capital of the Company has risen to Rs.15,57,23,720/- divided into 1,55,72,372 equity shares of Rs.10 each. BAL PHARMA LTD. - 524824 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shailesh Siroya